Previous clinical studies have reported the survivin expression to be associated with tumour cell proliferation, apoptotic inhibition, and a poor prognosis in various human cancers, including NSCLCs (Martinez et al, 2004; Shinohara et al, 2005). This evidence concerns the gene BIRC5 and cancer.